SEC Comment Letter for Rein Therapeutics, Inc. (RNTX) (CIK 0001420565) (RNTX) — May 23, 2019
Rein Therapeutics, Inc. (RNTX) (CIK 0001420565)
Date: May 23, 2019 · CIK: 0001420565 · Accession: 0000000000-19-008871
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-226650
Letter
May 23, 2019 CERTIFIED MAIL RETURN RECEIPT REQUESTED Manuel C. Alves Aivado, M.D., Ph.D. Chief Executive Officer Aileron Therapeutics, Inc. 490 Arsenal Way, Suite 210 Watertown, MA 02472 Re:Aileron Therapeutics, Inc. Registration Statement on Form S-3 Filed August 7, 2018 File No. 333-226650 Dear Mr. Alves Aivado: It has been more than nine months since you filed this registration statement and it is now out of date. Within 30 days from the date of this letter, you should either: •amend it to comply with the applicable requirements of the Securities Act of 1933, the rules and regulations under the Act, and the requirements of the form; or •file a request for withdrawal.
If you requested confidential treatment for portions of any exhibits to your registration statement and you request withdrawal of that registration statement, please submit a concurrent request for withdrawal of your application for confidential treatment. If you do not amend the registration statement or file a request for withdrawal (or provide us with a satisfactory explanation of why you have not done either) within 30 days, we may enter an order declaring the registration statement abandoned under rule 479 of the Act. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely,
FirstName LastNameManuel C. Alves Aivado, M.D., Ph.D. Comapany NameAileron Therapeutics, Inc. May 23, 2019 Page 2 FirstName LastName Manuel C. Alves Aivado, M.D., Ph.D. Aileron Therapeutics, Inc. May 23, 2019 Page 2 Division of Corporation Finance Office of Healthcare & Insurance cc: The Corporation Trust Company CERTIFIED MAIL RETURN RECEIPT REQUESTED
Show Raw Text
May 23, 2019
CERTIFIED MAIL
RETURN RECEIPT REQUESTED
Manuel C. Alves Aivado, M.D., Ph.D.
Chief Executive Officer
Aileron Therapeutics, Inc.
490 Arsenal Way, Suite 210
Watertown, MA 02472
Re:Aileron Therapeutics, Inc.
Registration Statement on Form S-3
Filed August 7, 2018
File No. 333-226650
Dear Mr. Alves Aivado:
It has been more than nine months since you filed this registration statement and it is now
out of date. Within 30 days from the date of this letter, you should either:
•amend it to comply with the applicable requirements of the Securities Act of 1933, the rules
and regulations under the Act, and the requirements of the form; or
•file a request for withdrawal.
If you requested confidential treatment for portions of any exhibits to your registration
statement and you request withdrawal of that registration statement, please submit a concurrent
request for withdrawal of your application for confidential treatment.
If you do not amend the registration statement or file a request for withdrawal (or provide
us with a satisfactory explanation of why you have not done either) within 30 days, we may enter
an order declaring the registration statement abandoned under rule 479 of the Act.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
FirstName LastNameManuel C. Alves Aivado, M.D., Ph.D.
Comapany NameAileron Therapeutics, Inc.
May 23, 2019 Page 2
FirstName LastName
Manuel C. Alves Aivado, M.D., Ph.D.
Aileron Therapeutics, Inc.
May 23, 2019
Page 2
Division of Corporation Finance
Office of Healthcare & Insurance
cc: The Corporation Trust Company
CERTIFIED MAIL
RETURN RECEIPT REQUESTED